Literature DB >> 28146666

Drug-Development Challenges for Small Biopharmaceutical Companies.

Richard A Moscicki1, P K Tandon1.   

Abstract

Mesh:

Substances:

Year:  2017        PMID: 28146666     DOI: 10.1056/NEJMra1510070

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

Review 1.  Building global development strategies for cf therapeutics during a transitional cftr modulator era.

Authors:  N Mayer-Hamblett; S van Koningsbruggen-Rietschel; D P Nichols; D R VanDevanter; J C Davies; T Lee; A G Durmowicz; F Ratjen; M W Konstan; K Pearson; S C Bell; J P Clancy; J L Taylor-Cousar; K De Boeck; S H Donaldson; D G Downey; P A Flume; P Drevinek; C H Goss; I Fajac; A S Magaret; B S Quon; S M Singleton; J M VanDalfsen; G Z Retsch-Bogart
Journal:  J Cyst Fibros       Date:  2020-06-07       Impact factor: 5.482

2.  The potential of polygenic scores to improve cost and efficiency of clinical trials.

Authors:  Akl C Fahed; Anthony A Philippakis; Amit V Khera
Journal:  Nat Commun       Date:  2022-05-25       Impact factor: 17.694

3.  The price of progress: Funding and financing Alzheimer's disease drug development.

Authors:  Jeffrey Cummings; Carl Reiber; Parvesh Kumar
Journal:  Alzheimers Dement (N Y)       Date:  2018-06-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.